Wedbush Securities Inc Fennec Pharmaceuticals Inc. Transaction History

Wedbush Securities Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$5.99 - $8.55 $412,669 - $589,035	-68,893 Closed	0 $0
Q3 2020 Oct 20, 2020	BUY	$5.19 - $10.17 $189,917 - $372,150	36,593 Added 113.29%	68,893 $417,000
Q2 2020 Jul 16, 2020	BUY	$5.43 - $9.39 $43,983 - $76,059	8,100 Added 33.47%	32,300 $270,000
Q1 2020 Apr 17, 2020	SELL	$4.89 - $8.1 $2,445 - $4,050	-500 Reduced 2.02%	24,200 $144,000
Q4 2019 Jan 16, 2020	BUY	$4.25 - $6.49 $54,400 - $83,072	12,800 Added 107.56%	24,700 $160,000
Q3 2019 Oct 17, 2019	BUY	$3.85 - $4.95 $45,815 - $58,905	11,900 New	11,900 $57,000

14.8M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $151M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.